Literature DB >> 6423722

Different rates of thyrotropin suppression after total body scan in patients with thyroid cancer: effect of an optimal saturation regimen with thyroxine or triiodothyronine.

B Busnardo, F Bui, M E Girelli.   

Abstract

The rate of TSH suppression in patients with differentiated thyroid cancer, when therapy is re-started after total body scan, was investigated adopting an optimal saturation regimen, either with T4 or with T3. The first group of 6 patients received T4 as follows: from day 1 to 7 = 22, 11, 6, 4, 3.5, 3.2, 3.2 micrograms/day/kg body weight (b w) and continued with 3.2; the second group of 8 patients received T3 as follows: 2.4, 1.8, 1.4, 1.2, 1.1, 1.1 micrograms/day/kg BW and continued with 1.1. At time 0, TSH levels were high in all patients (range 80-180 microU/ml); T3 and T4 levels were below the limit of detectability. After the beginning of the therapy, the decrease of TSH levels and the inhibition of TSH response to TRH occurred faster in patients taking T3 than in patients taking T4. In the former, at day 7, mean basal TSH level was 1.9 +/- 0.5 microU/ml and 30 min after 200 micrograms TRH iv mean TSH level was 9.9 +/- 4.4 microU/ml; at day 10 they were 1.4 +/- 0.5 and 2.7 +/- 0.8 microU/ml respectively. In the latter, at day 7, mean basal TSH level was 4.6 +/- 3.9 microU/ml and 30 min after TRH mean TSH level was 42.2 +/- 34.2 microU/ml. Only at day 20 they were 0.8 +/- 0.2 and 1.2 +/- 0.9 microU/ml respectively. In patients taking T3 by saturation regimen, serum levels of T3 rose rapidly to supranormal values (at day 3, mean serum T3 level was 297 +/- 62 ng/100 ml), reached a peak at day 5 (340 +/- 62 ng/100 ml) and decreased thereafter, always remaining however above normal limits.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6423722     DOI: 10.1007/BF03348345

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  17 in total

Review 1.  Nuclear receptors and the initiation of thyroid hormone action.

Authors:  J H Oppenheimer; H L Schwartz; M I Surks; D Koerner; W H Dillmann
Journal:  Recent Prog Horm Res       Date:  1976

2.  The contribution of local tissue thyroxine monodeiodination to the nuclear 3,5,3'-triiodothyronine in pituitary, liver, and kidney of euthyroid rats.

Authors:  J E Silva; T E Dick; P R Larsen
Journal:  Endocrinology       Date:  1978-10       Impact factor: 4.736

3.  Recovery of pituitary thyrotropic function after withdrawal of prolonged thyroid-suppression therapy.

Authors:  A G Vagenakis; L E Braverman; F Azizi; G I Portinay; S H Ingbar
Journal:  N Engl J Med       Date:  1975-10-02       Impact factor: 91.245

4.  Different rates of thyrotropin suppression after total body scan in patients with thyroid cancer: effect of regular doses of thyroxine and triiodothyronine.

Authors:  B Busnardo; F Bui; M E Girelli
Journal:  J Endocrinol Invest       Date:  1983-02       Impact factor: 4.256

5.  Suppression of the TSH response to TRH by thyroxine therapy in differentiated thyroid carcinoma patients.

Authors:  B A Lamberg; M Rantanen; P Saarinen; K Liewendahl; A Sivula
Journal:  Acta Endocrinol (Copenh)       Date:  1979-06

6.  Evidence of lower toxicity during thyroxine suppression after a single 3-mg L-thyroxine dose: comparison to the classical L-triiodothyronine test for thyroid suppressibility.

Authors:  K W Wenzel; H Meinhold
Journal:  J Clin Endocrinol Metab       Date:  1974-05       Impact factor: 5.958

7.  Inhibition of intrapituitary thyroxine to 3.5.3'-triiodothyronine conversion prevents the acute suppression of thyrotropin release by thyroxine in hypothyroid rats.

Authors:  P R Larsen; T E Dick; B P Markovitz; M M Kaplan; T G Gard
Journal:  J Clin Invest       Date:  1979-07       Impact factor: 14.808

8.  Twenty-four hour variations of triiodothyronine (T3) levels in patients who had thyroid ablation for thyroid cancer, receiving T3 as suppressive treatment.

Authors:  B Busnardo; M E Girelli; F Bui; G P Zanatta; M Cimitan
Journal:  J Endocrinol Invest       Date:  1980 Oct-Dec       Impact factor: 4.256

9.  Effects of a single high oral dose of thyroxine on the pituitary-thyroid-axis.

Authors:  H G Hoff; K Hackenberg; D Reinwein
Journal:  J Endocrinol Invest       Date:  1981 Jan-Mar       Impact factor: 4.256

10.  TSH synthesis and release in the thyroidectomized rat: b) effect of T3.

Authors:  O Spira; A Birkenfeld; A Avni; J Gross; A Gordon
Journal:  Acta Endocrinol (Copenh)       Date:  1979-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.